Hypolipidemic and cardioprotective benifits of Garden cress seeds in rats compared to atorvastatin
Amany A Salama, Naglaa M Ismael and Magdy Bedewy
The prevalence of elevated cholesterol and fasting-triglyceride concentrations is 36.7% and 10.2% in Egypt, and an estimated 46% of total fatalities are due to cardiovascular disease. Synthetic drugs with hypolipidemic efficacy are widely used; yet limitations for their use are prices and side effects. Safe and cheap alternatives are therefore natural products. Garden cress possesses several pharmacological properties and has a capability for functional food production. Aim was to explore the impacts of Garden cress seed powder (GSP) on lipid profile and C-reactive protein as a proxy marker of cardiovascular risk in rats fed a high fat diet (HFD) in comparison to atorvastatin. Application as a functional ingredient for incorporation in a real food model as biscuit, pizza and cupcakes was tested. Thirty five Wistar rats were distributed among five groups. Group I (control), group II (on HFD), group III (on HFD and GSP 10%), group IV (on HFD and GSP 15%rats), and group V (on HFD and Lipitor 15mg/kg/day). HFD resulted in significant increase in CRP levels compared to control group. Lipid profile was significantly higher than control rats for total cholesterol (TCh), triglycerides (TG), LDL, while HDL was significantly lower. Both doses of GSP caused significant decrease in CRP. GSP has a hypolipidemic activity and in a dose of 15% it is comparable to atorvastatin 15 mg/kg. Cardioprotective benifits of GSP by significantly reducing CRP levels is the novel finding in the present study.